Search results
Showing 181 to 195 of 277 results for coronavirus
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.
This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
This guideline covers how organisations, practitioners and carers should work together to deliver high-quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and have the same opportunities as their peers.
Lung texture analysis for measuring interstitial lung diseases (MIB272)
NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .
This quality standard covers care for women of any age (including girls and young women under 18) who request an abortion. It describes high-quality care in priority areas for improvement.
View quality statements for QS199Show all sections
Sections for QS199
- Quality statements
- Quality statement 1: Access to abortion services
- Quality statement 2: Choice of abortion procedure
- Quality statement 3: Waiting time for an abortion
- Quality statement 4: Early medical abortion
- Quality statement 5: Contraception
- Quality statement 6: Support after an abortion
- Update information
This quality standard covers care for adults before, during and after primary elective hip, knee or shoulder joint replacement. It describes high-quality care in priority areas for improvement. It does not cover joint replacement as treatment for primary or secondary cancer affecting the bones.
View quality statements for QS206Show all sections
Sections for QS206
- Quality statements
- Quality statement 1: Preoperative rehabilitation advice for hip and knee replacement
- Statement 2: Choice between partial and total knee replacement
- Statement 3: Tranexamic acid during hip and knee replacement
- Quality statement 4: Preventing implant selection errors
- Statement 5: Postoperative rehabilitation
- Update information
- About this quality standard
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.
Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood.
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.
Evidence-based recommendations on belantamab mafodotin (Blenrep) with pomalidomide and dexamethasone for previously treated multiple myeloma in adults.